Rhinomed Ltd (ASX:RNO) has launched two products into global markets during the financial year: launching our new sleep quality aid, Mute(TM) into the global sleep device market and a new generation Turbine(TM) sports product in response to feedback from users.
Rhinomed Limited (ASX:RNO) is a Melbourne, Australia based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is developing and commercialising applications of its technology portfolio in the sport, sleep, cough/cold and allergy, and drug delivery markets. The company has two products in market (the Turbine for sports and exercise and Mute for snoring and better sleep) and has recently completed a pilot Phase I clinical trial of its new INPEAP technology targeting mild to moderate sleep apnea. For more information, go to www.rhinomed.global.
Rhinomed Limited (ASX:RNO) is pleased to announce today that it has raised a total of A$2.5m by a way of a placement of 78,125,000 fully paid ordinary shares at A$0.032 per shares with institutional, Sophisticated, and Offshore investors (placement).
Australian respiratory technology company, Rhinomed (ASX:RNO) is pleased to announce it has entered into a landmark partnership with SleepGP, a growing network of GP practices, to raise awareness of sleep disordered breathing issues within the family medicine setting.
Rhinomed Ltd (ASX:RNO) has been building its international presence and connections amongst the international investment and pharmaceutical community this year. In March, Michael Johnson was the keynote 'Rising Star' presentation at the Master Investor Show in London.
Australian respiratory technology company Rhinomed Ltd (ASX:RNO) is pleased to advise it has increased its production line capacity at the ChinaMed production facility.
Australian respiratory technology company Rhinomed Ltd (ASX:RNO), is pleased to announce its Mute snoring and sleep technology will be available on pharmacy shelves in the United Kingdom from late October 2015.
Key highlights of the quarter included the growing demand for the company's new Turbine design and strong early demand for the Mute snoring and sleep technology. Receipts from Customers for the quarter were up $33k to $192k. Revenues from the Australian pharmacy channel will be included during the next quarter
2013 Tour de France Yellow Jersey Winner Chris Froome Appointed as Rhinomed Ltd's (ASX:RNO) Turbine Ambassador
Rhinomed Ltd (ASX:RNO) an Australian company focused on the development of novel nasal and respiratory technology today announced 2013 Tour de France Yellow Jersey winner Chris Froome has joined as its new Turbine(TM) Global Ambassador.
Rhinomed Ltd (ASX:RNO) announce the 2015 BIO International Convention Presentation.
Rhinomed Ltd (ASX:RNO), an Australian company focused on the development of novel nasal and respiratory technologies, today announced that it has received Monash Health Human Research Ethics Committee (HREC) approval for its inaugural Phase 1 sleep apnea trial featuring its new Intranasal Positive Expiratory Airway Pressure (INPEAP) technology.